Skip to main content
. 2022 Mar 18;10(3):e004316. doi: 10.1136/jitc-2021-004316

Figure 2.

Figure 2

Association of genomic biomarkers with survival. (A) Forest plot for PFS comparing high (≥median) vs low TMB, high (≥median) vs low TIB, and heterozygous vs homozygous HLA in the nivolumab plus ipilimumab and the sunitinib arms. (B) Forest plot for OS comparing high (≥median) vs low TMB, high (≥median) vs low TIB, and heterozygous vs homozygous HLA in the nivolumab plus ipilimumab and the sunitinib arms. (C) Representation of mutations found across both treatment arms in seven selected genes. (D) Forest plot of PFS by mutation status. (E) Forest plot of OS by mutation status. Forest plots show HRs and 95% CIs for given comparisons, and p values compare patient subgroups within each treatment arm. Het, heterozygous; HLA, human leukocyte antigen; Homo, homozygous; IPI, ipilimumab; MUT, mutant; NIVO, nivolumab; OS, overall survival; PFS, progression-free survival; SUN, sunitinib; TIB, tumor indel burden; TMB, tumor mutational burden; WES, whole-exome sequencing; WT, wild type.